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Intenstve CllnicPl lnvestlgatton has led to the acceptance of 
many fundumentul aspect3 of reperfuslon therapy, espe- 
ehlly its satutory elkcts on improved survival, left ventric- 
ulor function and reduced infarct size. However, many 
ilnresdvedlmuesllrecurrentlybctngaddressedurwtuhe 
tk focus nf future clintcal trtats. These inchute p&znt 
s&etioawithrespeettoriskprotitesndttnteofpresenta- 
The field of thromholytic reperfusion of acute myocardial 
infarction is now moving forward at a very rapid pace, with 
important new observations being recorded on an almost 
weekly basis. It may be useful, from time to time, to pause 
and take stock of the current status of this field and to point 
out those issues regarding this important new form of 
therapy that appear to have been resolved and those that still 
remain unresolved. 
Wesolved kwes (Table 1) 
There is no longer any doubt that the intravenous admin- 
istration of thrombolytic agents early in the course of myo- 
cardial infarction in patients who present with ST segment 
elevation frequently causes reperfusion of reversibly injured 
myocardium and thereby may reduce infarct size, limit left 
ventricular dysfunction and reduce both early and late 
mortality. 
Reduction in mortality. Powerful new evidence for !he 
ability of thrombolytic therapy to reduce mortality was 
provided in this symposium by the Second International 
Study of Infarct Survival (ISIS-2) Collaborative Group (I), 
who studied the effectiveness of streptokinase and aspirin 
separately and together, and by the European Cooperative 
Grotip (2). who studied recombinant tissue plastinogen 
activator (rt-PA). One unexpected finding in the ISIS-2 was 
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tion, the choiie of a thmmb+ttc age=:, the rate of pdjtu~- 
coronary revascnla 
with spitic attention to tiee lnlporlont yet 
(I Am Cdl Car&l 1988;12:85A-92A) 
that the administration of streptokinase and aspirin, as late 
as 12 to 24 h after the onset of symptoms, improved the 
survival rate. This observation differs from that of other 
recent studies of thrombolysis in acute myocardial infarction 
(i-&ding :hc Puruppo it&no per lo Studio delta Strepro- 
chinasi nell’lnfarto Miocardico [GISSI] trial (31) and it is 
tion that aspirin alone also improved survival. These tindings 
should direct careful attention to the chzuacteristics of the 
patients entered into the trial lo be certain that the vast 
majority did, in fact, have myocardial infarction. In the 
ISIS-2 study, the treating physicians could avoid entering 
otherwise eligible patients into the trial if they felt that the 
fraction of randomizable pa- 
and if so how, this feature of 
trial design influenced the results. Regardless of these con- 
siderations, the ISIS-2 trial is an extremely valuable trial 
since it demonstrated in a large number of patients studied in 
a wide variety of clinical settings that both a thrombolytic 
agent and a platelet antiaggregatory agent, and especially the 
combination. could reduce the early (5 week) mortality in 
patients presenting with acute miocardial ischemic syn- 
brjmes including acute myocardiil infarction. 
An important and interesting feature of the European 
Cooperative trial (2) was the extremely low mortality, both 
in the placebo-treated (5.7%). but especially in the R-PA- 
treated (2.8%) oaatients at 14 days. It is obviwsly much more 
difficult for an intervention to improve survival in a setting in 
which the mortalitv rate in the control (or placeM:eated) 
patients is as low&it was in the European &operative trial, 
Q19SS by the Amsrkon Colkge of Cardiology 
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compared with 13.0% in GISSI (3) and 13.2% in ISIS-2. The 
mortality rate of 2.8% in the rt-PA-treated patients in the 
European trial is the lowest mortality rate for acute myocar- 
dial infarction in any trial of this size of which 1 am aware. 
Comparison between streptoklnase and rt-PA. There have 
been two trials (4-6) that compared the efficacy of intrave- 
nous rt-PA with streptokinase in lysing coronary thrombus 
and establishing coronary artery patency (three trials if the 
sequential open label TIM1 studies l7,81 are considered), and 
all have demonstrated the superiority of &PA in this regard. 
However, it has been proposed that this difference may be of 
little if any clinical significance, since, according to this 
suggestion, rt-PA ie more efiective than streprokinase only in 
lysing relatively old thrombi; the latter is unlikely to salvage 
much myocardium (9), but the two agents are said to be 
almost equally effective In lysing fresh thrombi. Therefore, it 
has been suggested that the two agents are really equieffec- 
tive in salvaging myocardium. However, the available data 
are not consistent with this suggestion. When data horn the 
two double-blind randomized “head to head” comparisons 
of these two thrombolytic agents (the TIMI I trial [4,6] and 
European Cooperative Study Group trial 15,101) are com- 
bined (Fig. I), two features are clear. First, not surprisingly, 
each agent is more effective in lysing fresh than older 
thrombi. However, rt-PA is superior to streptokinase xn 
achieving coronary artery patency not only in patients who 
were treated relatively late, but also in those treated rela- 
tively early (lOa). Since the quantity of myocardium sal- 
vaged by thrombolysis varies inversely with the time after 
the onset of infarction that reperfusion is achieved, it is 
desirable to maximize the possibility of successful reperfu- 
sion, especially in patients treated in the earliest hours after 
the onset of symptoms. 
Recombinant tissue plasminogen activator is more fibrin- 
specific than is streptokinase (5,9,1Oa,Il,l2,13) and, there- 
fore, causes less perturbation of the coagulation system, 
with less breakdown of ccxgu!ation factors V and V!!I and 
fibrinogen. Initial trials comparing these two agents were 
designed to assess their relative thrombolytic efficacy and, 
therefore, involved patients who underwent cardiac cathe- 
tcrization and who were extensively instrumented. Bleeding 
occurred frequently after the administration of both agents 
n 30 68 10s 108 
48 h 3-O h 
FIgare 1. Combined result8 of the l’hrombolysis in Myocardial 
Infarction (TIMI) (4.6) and European Cooperative (SJO) trids, 
comparing the effectiveness of 8tnptokinaJe (S) and tissue plasmin- 
ogen activator (t-PA) in achieving coronary artery patency accord- 
ing to the time of treatment (see Ref. IUa). 
(5,6,ll) and occurred most commonly at sites of vascular 
entry. In one trial (5.12), there was a suggestion that rt-PA 
caused less bleeding than did streptqkinase. Whether or not 
the superior profile of r&PA in terms of circulating coagula- 
tion factors will be translated into a lower incidence of 
dangerous hemorrhage remains to be demonstrated. Opti- 
mally, such a comparison should be carried out in patients 
with no or minimal vascular invasion. It will be important to 
determine the relative rates of intracranial, gastrointestinal 
and genitourhuuy bleeding caused by Iysis of protective 
fibrin plugs. This information should become available from 
the ongoing GISSI-II and the planned ISIS-3 studies. 
After successful tht vmbolysis, most patients are left with 
a critical obstruction of the infarct-related coronary artery 
and are at high risk of reocclusion. Because reocclusion 
occurs more frequently in the presence of severe residual 
coronary artery narrowing (14), it has been suggested, and it 
seemed logical, that reocclusion could be averted if coronary 
angioplasty was carried out immediately after thtombolysis. 
However, it is now clear from three separate trials-TAM1 
(IS), the European Cooperative study (16) and TIMI-IIA 
(17)-that cotona,, arteriography followed by angioplasty is 
not necessary as a routine measure immediately after intra- 
venous thrombolytic therapy, and, in fact, is probably un- 
desirable. 
Unresolved Issues 
Patient Selection (Table 2) 
Patlent with Inferior waII infaretlun. There is a good deal 
of controversy about the potential value of thrombolytic 
therapy in patients with inferior wall myocardial infarction. 
Some studies (lg-21) have shown that such patients are 
benefited by thtombolysis, although usually less so than 
patients with anterior wall infarction. In the GISSI trial (3), 
patients with inferior wall infarction exhibited no imptove- 
ment in survival. This is understandable when we consider 
that, when corrected for infarct size, the extent of impait- 
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ment of left ventricular functron caused by inferior wall 
infarction is about half of that produced by anterior wall 
infarction (22). Thus, a moderate-sized inferior wall infarc- 
tion may he considered equivalent to a small anterior wall 
infarction with respect to impairment of left ventricular 
function, and the prognosis for both short- and long-term 
survival is usually excellent; it is thus more difficult to 
demonstrate improved outcome with an inferior infarction 
than with a comparably sized anterior infarction. Therefore. 
it would appear reasonable to set the threshold for throm- 
holytic therapy higher for patients with inferior than for 
those with anterior wall infarction. The potential benefits of 
thrombolytic therapy probably outweigh the disadvantages 
(that is, the risks and cost+ in patients with a large inferior 
wall infarct with hemodyna.uic instability who can be treated 
within approximately 3 h of the onset of symptoms. How- 
ever, the potential benefits are probably less in patients with 
an inferior wall infarct who are stable hemodynamically and 
who present at a later time. Such patients almost uniformly 
exhibit an uncomplicated course without thrombolyric tbcr- 
apy, and one must consider the small risk of serious bleed- 
ing. 
Patknts with ST &pmmiun. The role of thrombolytic 
therapy in patients who present with ST segment depression 
only is also unresolved. In most of the trials of thromholytic 
therapy (GISSI and IS!S2 were exceptions), ST segment 
elevarion was a critical criterion for patient inclusion. In the 
GlSSl trial (3). patients with ST segment depression (like 
those with inferior wall infarction) did not show any im- 
provement in survival ;vhen treated with streptokinase. 
There are SeVed possible explanations for this finding. 
Fist, the evidence that infarction in patients with ST seg- 
ment depression is caused by persistent coronary thrombus 
is less secure than it is for patients with ST segr?:cnt 
elevation; indeed, patients with ST segment depression may 
already have spontaueous lysis of their thrombi at the time 
they are first seen. Second, their infarct tends to be smaller 
and, like patients with inferior wall infarction, they tend to 
exhibit less left ventricular dysfunction and in the short term 
to have a better prognosis than do patients with ST segment 
elevation and Q waves (22). Therefore, the demonstration of 
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Persistent patn as a marker of residual viable ischemic 
t&sue. Studies on anesthetized dogs in many laboratories 
have shown that little if any myocardial salvage occurs when 
repetfusion is canied out more than 3 h after coronary 
occlusion; this time interval is even shorter in the nonhuman 
primate and the pig, in which coronary collateral vessels are 
less well developed than in the dog. However, in clinical 
practice, it is often dificult to time precisely the onset of 
myocardial infarction, especially in patients with a “stut- 
tering” infarction. If ischemic pain persists, even for more 
than 5 or 6 h, it is likely that some reversibly injured, 
potentially salvageable myocardium persists; necrotic myo- 
cardium probably causes no ischemic pain. Can persistence 
of ischemic chest pain be used as a marker of residual 
viability of ischemic tissue? 
Preventing infarct expansion and residual dilation. If in- 
farction is complete or almost so by 4 to 6 h after the onset 
of symptoms, is there any rationale for late thrombolytic 
therapy? There appears to be little improvement in left 
ventricular function (26). However, there may be another 
reason for wishing to restore coronary artery patency. It is 
now clear that, after acute myocardial infarction, a complex 
remodeling of the left ventricle occurs: this involves expan- 
sion of the infarct and dilation of the noninfarcted portion of 
the ventricle (26-29). McKay et al. (3@) and F’fefler et al. (31) 
assessed geometric changes in the left ventricle by angiog- 
raphy in patients with a tirst acute transmural myocardiai 
infarction. A significant increase in left ventricular end- 
diastolic and end-systolic volumes occurred; the increase in 
the latter correlated with the percent of ihe ventricular 
silhouette that was akinetic or dyskinetic. It has been 
proposed (30) that infarction reduces the ejection fraction, 
which raises left ventricular end-diastolic volume and pres- 
sure, thereby increasing wall stress. The latter lead to infarct 
expansion and dilation of the noninfarcted segment, and 
both of these combine to cause late heart failure. Qualita- 
tively similar observations in patients have been made with 
echocardiography (32). It hes also been established that 
progressive enlargement of the left ventricle is an ominous 
prognostic sign, &en presaging the development of left 
ventricular failure and death. 
It is possible that #he /are establishment ofpatency of the 
infarct-related artery will reduce left ventricular dilation. 
Several observations are consonant with this hypothesis. 
For example in the Western Washington Intracoronary 
Streptokinase trial (33), patients were randomized an aver- 
age of 4.5 h after the onset of symptoms. Those who had 
complete perfusion of the infarct-related artery had a I year 
mortality rate of 5%. whereas patients with partial or no 
reperfusion had a 35% morttlity rate, even though there was 
no difference in the ejection fraction between these groups. 
Fung et al. (34) reported that coronary angioplasty per- 
formed an average of 5 h after the onset Gt myocardiai 
infarction and after unsuccessful streptokinase therapy re- 
sulted in a striking improvement in ejection fraction. In those 
studies, reperfusion was probably carried out too late to 
salvage substantial quantities of myocardium, yet establish- 
ing patency of the infarct-related artery appeared to be 
beneficial. 
Before the use of thromboiytic therapy, Verheugt et al. 
(35) reported that left ventricular ejection fraction measured 
by radionuclide ventriculography increased in the patients 
who underwent spontaneous reperfusion, and decreased in 
the patients without spontaneous reperfusion. Similarly, 
Jeremy et al. (36) compared left ventricular volumes 48 hand 
I month after infarction. Dilation, defined as at least a 20% 
increase in left ventricular end-diastolic volume,was noted in 
all patients without spontaneous reperfusion of the infarct- 
related artery, but only very rarely in patients who had 
spontaneous reperfusion of this artery. Multiple regression 
analyses confirmed that the degree of perfusion of the 
infarct-related artery was an important (inverse) predictor of 
increase in ventricular volume. Other investigators (37,38) 
also observed that spontaneous reperfusion of the infarct- 
related artery was associated with improved left ventricular 
function. 
Late myucardial salvage. When taken together, these 
observations are consistent with the hypothesis that even 
late reperfusion occurring in the absence of substantial 
myocardiai salvage might favorably influence the outcome 
after acute myocardial infarction. The mechanism for such a 
salutary effect, if it exists, is not clear. One potential benefit 
accruing from late reperfusion is that the reopened infarct- 
related artery may reduce infarct expansion, left ventricular 
remodeling arid dilation. It may also, through collateral 
vessels, supply areas of myocardium in the territory of other 
diseased vessels and thereby preserve myocardial viability. 
The possibility that some myocardial salvage can occur as 
late as 6 to 8 h after the onset of symptoms should not be 
dismissed. Although the volume of myocardium salvaged by 
successful reperfusion at this time is probably minimal, the 
myocardium that is salvaged is like!y to be an epicardial rim, 
which might prevent infarct expansion and subsequent re- 
modeling of the noninfarcted myocardium. Finally, it is 
possible that late myocardial reperfusion may reduce the 
incidence of late ventricular fibrillation (39) and thereby be 
of clinical benefit. This possibility is discussed in greater 
detail elsewhere (39a). 
Thrombolytic Agents (Table 3) 
Other benetkial effects of tlnombolytk agents. An unre- 
solved issue concerning the use of thromboiytic agents is 
whether streptokinase exerts salutary properties in addition 
to causing coronary thromboiysis. The unusual effectiveness 
of streptokinase in reducing mortality in GISSI-I (3), espe- 
cially the 47% reduction in mortality rate observed in pa- 
tients treated within I h of the onset of symptoms, the 
impressive effects on survival in the much smailer New 
Zealand trial (20). the substantial reduction in mortality 
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Tahk 3. Unresolved Issues in Tbrombolytic Therapy: 
Thrombolytic Agents 
-  
I. Doe> strcptokinasc have salutary propentes other than causmg 
thmmbolyris? 
2. HOW does acylated stnptokinase (APSAC) compare wth streptokinase 
and recombinanl tissue type plasmirmgen activator @t-PA) 
3. Will the supuiorily ofn-PA in coronary thrombotyris be tnndated mto 
improved ventricular function and survivals 
4. Is there synergism between single chain urokina% type plasminogen 
activator aad rt-PA? 
5. What are the potential roles of “third generation” thrombolyllc agent% 
(mutants of ri-PA. thrombolytic agents altached to antifibrin monoclonal 
antibodies)? 
6. WhaI are the ideal pharmacokioetics of thrombolytic agentc” Should the 
half-time be short. intermediate or  long? 
achieved with acylated streptokinase (APSAC) in the AIMS 
trial (40), coupled with the less impressive results with 
streptokinase with respect to coronary thrombolysis (4 
6,8,41), at least raise the possibility that this drug may have 
other, as yet undefined, beneficial actions. Also lrnresolved 
is where APSAC fits into the picture of currently available 
thrombolytic agents; there have been no studies in which it 
has been compared directly with the more widely used 
intravenous streptokinase and r&PA, although a recent mul- 
ticenter trial (42) found that APSAC was equally effective as 
intravenous streptokinase. Similarly, not enough is known 
about urokinase; preliminary results of one trial with intra- 
venous urokinase reported impressive coronary throm- 
bolysis. similar to that achieved with rt-PA (43). 
Another important, but as yet unresolved, issue is 
whether the aforementioned superiority of rt-PA over strep- 
tokinase insofar as causing coronary reperfusion will be 
translated into improved left rcuut,.dar function and sur- 
vival. Up to now, both drugs have, in several separate 
studies (3,I8-21), proved superior to placebo in this regard. 
The GISSI-2 trial is (as will the ISIS-3 trial) compalng the 
effects of these agents on survival. 
Syuergknm helweeu thnuubelytlc agents. There is evi- 
dence from studies carried out in vitro (44.45). in experimen- 
tal animals (46) and on a limited number of patients (47.48) 
that there may be synergism between the actions of single 
chain urokinase plasminogen activator (scu-PA. pro- 
urokinase) and r&PA. If codrmed, this synergism could 
lead to the use of small doses of both drugs, resulting in 
greater fibrin specificity than from the use of either agent 
alone. It has also been suggested (49) that mutant forms of 
rt-PA (deletions, additions or substitutions) as well as chi- 
meric molecules containing the fibrin recognition site of 
&PA and the protease activity of scu-PA may be more 
llbrin-specific than native rt-PA. Finally, the coupling of 
r&PA (and other thrombolytic agents) to antifibrin monoclo- 
nal antibodies also improves fibrin specificity (SO). Theoret- 
ically, all of these alterations in thrombolytic agents might be 
beneficial, but other than the preliminary studies on the 
Table 4. Unrewlvrd issues 
Adjonclwe Agent5 
in Thrombolytic Therapy: 
I. Ro!e of hepann and of antipfatekt agents in knwing iacideace of 
reoccluwm and reduc ing dose of thrombotytic agent 
3. Role of beta-biocker (and cakiom angataistst. which delay ixhemic 
cell death m enhawing myocardial salvage 
3. Role of agents that ravenge (or  inhthit formation 00 free radiials m 
reducmg repvrusmn mjury and enhancing myocardiol salvage after 
thrombolvsls 
Adjlrnctive Therapy (Table 4) 
Use of heparht aud aeplrle. In many trials, heparin has 
been used together with a thrombolytic agent in the hope of 
preventing coronary reocclusion, but its value has not been 
established. In many other trials. aspirin has been employed; 
in still others, the combination of heparin an< aspirin was 
used. In some trials, notably the GISSI trial (3). neither drug 
was employed, yet the results in terms of patient survival 
were salutary. ISIS-2 (I) is the only trial in which the effect 
of one of these adjunctive agents (aspirin) was assessed 
prospectively and in a randomized manner; although aspirin 
enhanced the elllcacy of streptokinase in relation to survival, 
it is not clear whether it acted by preventing reinfarction or 
by preventing the initial coronary occlusion, as discussed 
earlier. 
Use ef antlceaguhtnk and sntlplatelet ageak. Other anti- 
coagulants, such as activated protein C, and a whole array of 
antiplatelet agents are now on the horizcn. These include 1) 
monoclonal antibodies to the platelet membrane receptor 
glycoprotein IIB-IIIA (5152). which are extremely potent 
antiaggregatory agents: and monoclonal antibodies to plate- 
let receptor glycoprotein IB (53), which blocks platelet 
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adhesion to the von Willebrand factor: 2) inhibitors of 
thromboxane A, synthetase; and 3) blockers of thromboxane 
A, receptors and serotonin (SHT,) receptors. Although these 
antiplatelet agents enhance thrombolysis in experimental 
preparations. their clinical value remains to be demon- 
strated. I believe that some form of antiplatelet therapy will 
ultimately prove to be beneficial in reducing the incidence of 
reocclusion after thrombolytic therapy; if this can be accom- 
plished without causing excessive bleeding, it will become 
routine adjunctive therapy to thrombolysis. 
Agents to delay cell death. The role, if any, of agents that 
delay cell death, such as beta-adrenergic blockers and cal- 
cium antagonists, as adjuncts to thrombolytic therapy in the 
management of acute myocardial infarction is also unre- 
solved. In experimental preparations with sustained coro- 
nary occlus;on, these agents often do not reduce infarct size 
(25). but they do appear to do so when administered before 
reperfubion (54). Also, there is evidence that the early 
administration of a beta-blocker reduces infarct size (55) and 
mortality (56) in patients with acute myocardial infarction. 
The TIMI-IIB trial is currently testing whether metoprolol, a 
beta, selective antagonist, is beneficial in patients treated 
with rt.PA. Calcium antagonis:s may also protect the reper- 
fused myocardium in experimental animals (57-59). but their 
potential benefit in patients treated with thrombolytics is 
unresoived 
Treatment with free radical scavengers. Oxygen-derived 
free radicals are formed when ischendc myocardium is 
reperfused (60). These highly reactive species can injure 
myocardial cells by causing peroxidation of cell membranes. 
It has been demonstrated in experimental animals that 
treatment with free radical scavengers, such as superoxide 
dismutase (61). sometimes combined with catalase (62) and 
with iron chelators that prevent the formation of free radicals 
(63). can limit myocardial damage and thereby enhance the 
quantity of myocardium salvaged by repcrfusion. It is not 
yet clear whether this approach will be useful in patients 
treated with thrombolytic agents; a clinical trial using human 
superoxide dismutase is currently underway. 
Mechanical Revascdarization (Table 5) 
Teehniques to predict or detect thrombolysis failure, Ap 
proximately 20 to 25% of patients with acu:e myocardial 
infarction treated with optimal doses of intravenous rt-PA do 
not exhibit immediate reperfusion The best strategy to 
achieve reperfusion in these patients has not been defined. 
First, it is necessary IO identify the patients who have failed 
thrombolytic therapy, preferably by noninvasive techniques, 
but those techniques that are readily available have not been 
found to be sufficiently accurate to be useful (64) and the 
search for noninvasive predictors continues. Perhaps other 
noninvasive techniques such as myocardial perfusion imag- 
Table 5. Unresolved Issues in Thrombolytic Therapy: 
Mechanical Revascularization - 
I. HIV 10 identify patients who may be lhrombolysis failures and s&cl 
those appropriate for immediate cardiac catheteriation coronary 
ing with isonitrile or positron emission tomography will be 
helpful in this regard. 
Emergency coronary arteriography. In the absence of an 
accurate, readily available noninvasive technique, should 
coronary arteriography be carried out on an emergent basis 
immediately after thrombolytic therapy to identify patients 
with persistently occluded vessels so that these patients may 
be considered for treatment by means of percutaneous 
transluminal coronary angioplasty? As already pointed out, 
the results of three separate trials (E-17) suggest that 
emergency angioplasty carried out routinely on all suitable 
patients immediately after thrombolytic therapy is usually 
not beneficial and may actually be harmful. However, the 
question of limiting emergency angioplasty to patients who 
have failed thrombolytic therapy is unresolved. On the one 
hand, as already discussed, it is desirable to achieve coro- 
nary reperfusion. On the other hand, both the TAM1 (65) and 
TIM1 investigators have commented on the high frequency 
of complications associated with “rescue angioplasty” in 
patients who have failed rt-PA therapy. Thus, the approach 
to the identification and treatment of these patients is unre- 
solved at this time. 
Routine elective coromwy arteriagraphy and angioplasty. 
An even larger question concerns the role, if any, of routine 
elective coronary arteriography followed, if necessary and 
feasible, by mechanical revascularization after the dissipa- 
tion of the thrombolytic state, but before the patient’s 
discharge from the hospital. It has been argued that because 
patients with evolving infarction are usually left with severe 
residual obstruction after thrombolytic therapy (14) and 
because coronary angioplasty is usually well tolerated and 
successful when carried out on an elective basis after the 
lytic state has dissipated (66). it is desirable routinely to 
perform coronary arteriography, followed by mechanical 
revascularization if severe obstruction persists in patients 
receiving thrombolytic therapy for acute niocardial infarc- 
tion. Indeed, this has become the standard of therapy 
employed by many physicians. Th . ..e va!ne of this strategy as 
compared with the more conservative course of performing 
these procedures only for spontaneous or provokable ische- 
mia has not been established, but is being addressed by the 
ongoing TIMl-1IB trial (66). If routine nonemergent coro- 
na:y angiography and angioplasty prove to be beneficial in 
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patients who have received thrombolytic therapy, it will / I Rae I# F’mrt C. Bsrkc A E( al. Thrombnlyuc I” Myocardtal Infarcdon 
substantially increase the cost and complexity of care of (TIMI) wd-phax I. hemorrhagic mamfea+w”=+ and changes in plaw~ 
patients with acute myocardiai infarction. Therefore. it i5 of 
A>nno~rn and the Rbrinolyw syclem in plienl~ rrcsled wlh recombinanl 
iawe pla$mmopn activa!“r and areptolwase. J Am Coil Cardiil 19% 
critical importance to resolve this issue. II I-II 
12. S&l BE Safety and e8icacy of liswe-type pl.wmmogen ac11valor 
Conclusions 
prcduccd by recombma”r DNA technology J Am Coil Cardiol 19%~10’5: 
MB-4B 
The initial promising results of thrombolytic therapy of 13. Collen D. &a”ameaux H, De Cock F. Lijnen HR. Verntraete M. 
acute myocardial infarction have greatly and probably per- Analyw of coaza:adon and fibnnolyris during intravenouc infwon of 
manently altered the care of patients with this condition. 
recombmanr huw,ar tissue-type pl=minogt” actwakx v! ~lmn!: w:h 
acute myccardii infarclicn. Circularion 1986.73:511-7. 
Thrombolytic reperfusion is likely to become as important a 
component of coronary care as antiarrhythmic therapy has 
I4 Badger RS. Brow EC, Kc”“cdy JW, et al. Usefulness of recznalilalmn 
to lummal dwwcr of 0.6 mm or  more with intraommary ptrep(okmau 
become. However, as occurs frequently, both in science and 
in clinical medicine, a major advance soon leads to the 
identification of a large number of additional questions. This 
is certainly the case for thrombolytic reperfusion of acute 
myocardial infaction. Despite the dramatic progress in tlus 
field, indeed perhaps becaltse of this progress, the number of 
unresolved issues identified in this report greatly exceed% !he 
number of resolved issues. The capacity to answer these 
new questions certainly exists. Once obtained, the appropri- 
ate application of these answers is certain to improve further 
the care of the patient with acute myocardial infarction. 
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